JAHA:无心血管疾病的右束支传导阻滞患者死亡率分析

2020-09-15 MedSci原创 MedSci原创

没有CVD的RBBB患者全因死亡、心血管相关死亡和运动耐受性降低的风险增加。这些数据表明RBBB可能是早期CVD的标志,值得进一步开展前瞻性评估。

人群中有0.2%至1.3%个体发生右束支传导阻滞(RBBB),其被认为是良性疾病。但是,一些研究表明,这类患者血管疾病发病率和死亡率的风险增加。近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员旨在评估无心血管疾病(CVD)个体归因于RBBB的风险。

研究人员审查了梅奥诊所综合负荷中心数据库中1993年到2010年期间进行的运动负荷测试,选择了没有CVD(定义为无冠心病、结构性心脏病、心力衰竭或脑血管疾病)的患者。研究人员仅纳入了明尼苏达州居民,他们全部都有完整的死亡和结局数据。

随访6至23年(平均为12.4±5.1),在22806例未确诊CVD的参与者中,220人(0.96%)患有RBBB。妇女为8256名(36.2%),平均年龄为52±11岁;随访期间1837人死亡(8.05%),包括645例心血管相关死亡(2.83%)。在根据年龄、性别、糖尿病、高血压、肥胖症、当前和过去吸烟史以及使用降低心率的药物进行调整后,RBBB可以预测全因(风险比[HR]为1.5;95%CI为1.1–2.0;P=0.0058)和心血管相关死亡(HR为1.7;95%CI为1.1-2.8;P=0.0178)。RBBB患者具有更高的血压(34.1% vs. 23.7%,P<0.0003),功能有氧运动能力下降(82±25% vs. 90±24%;P<0.0001),心率恢复较慢(13.5±11.5 vs. 17.1±9.4 bpm;P<0.0001),运动测试时出现呼吸困难(28.2% vs. 22.4%;P<0.0399)。

由此可见,没有CVD的RBBB患者全因死亡、心血管相关死亡和运动耐受性降低的风险增加。这些数据表明RBBB可能是早期CVD的标志,值得进一步开展前瞻性评估。

原始出处:

Prakriti Gaba.et al.Mortality in Patients With Right Bundle‐Branch Block in the Absence of Cardiovascular Disease.J AM HEART ASSOC.2020.https://www.ahajournals.org/doi/full/10.1161/JAHA.120.017430

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1983685, encodeId=b8e51983685e1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Nov 20 22:07:02 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033953, encodeId=b8282033953e0, content=<a href='/topic/show?id=0edb25862cb' target=_blank style='color:#2F92EE;'>#传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25862, encryptionId=0edb25862cb, topicName=传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Fri Feb 26 09:07:02 CST 2021, time=2021-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268325, encodeId=8d42126832585, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Sep 17 03:07:02 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498771, encodeId=a13a1498e71c5, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Sep 17 03:07:02 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885610, encodeId=114b88561058, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/27/9fdee81ba9771b6af046150adc14ee91.jpg, createdBy=54572576350, createdName=绝望的人没有故乡, createdTime=Wed Sep 16 07:47:34 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1983685, encodeId=b8e51983685e1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Nov 20 22:07:02 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033953, encodeId=b8282033953e0, content=<a href='/topic/show?id=0edb25862cb' target=_blank style='color:#2F92EE;'>#传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25862, encryptionId=0edb25862cb, topicName=传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Fri Feb 26 09:07:02 CST 2021, time=2021-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268325, encodeId=8d42126832585, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Sep 17 03:07:02 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498771, encodeId=a13a1498e71c5, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Sep 17 03:07:02 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885610, encodeId=114b88561058, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/27/9fdee81ba9771b6af046150adc14ee91.jpg, createdBy=54572576350, createdName=绝望的人没有故乡, createdTime=Wed Sep 16 07:47:34 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1983685, encodeId=b8e51983685e1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Nov 20 22:07:02 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033953, encodeId=b8282033953e0, content=<a href='/topic/show?id=0edb25862cb' target=_blank style='color:#2F92EE;'>#传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25862, encryptionId=0edb25862cb, topicName=传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Fri Feb 26 09:07:02 CST 2021, time=2021-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268325, encodeId=8d42126832585, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Sep 17 03:07:02 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498771, encodeId=a13a1498e71c5, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Sep 17 03:07:02 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885610, encodeId=114b88561058, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/27/9fdee81ba9771b6af046150adc14ee91.jpg, createdBy=54572576350, createdName=绝望的人没有故乡, createdTime=Wed Sep 16 07:47:34 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
    2020-09-17 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=1983685, encodeId=b8e51983685e1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Nov 20 22:07:02 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033953, encodeId=b8282033953e0, content=<a href='/topic/show?id=0edb25862cb' target=_blank style='color:#2F92EE;'>#传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25862, encryptionId=0edb25862cb, topicName=传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Fri Feb 26 09:07:02 CST 2021, time=2021-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268325, encodeId=8d42126832585, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Sep 17 03:07:02 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498771, encodeId=a13a1498e71c5, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Sep 17 03:07:02 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885610, encodeId=114b88561058, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/27/9fdee81ba9771b6af046150adc14ee91.jpg, createdBy=54572576350, createdName=绝望的人没有故乡, createdTime=Wed Sep 16 07:47:34 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1983685, encodeId=b8e51983685e1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Nov 20 22:07:02 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033953, encodeId=b8282033953e0, content=<a href='/topic/show?id=0edb25862cb' target=_blank style='color:#2F92EE;'>#传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25862, encryptionId=0edb25862cb, topicName=传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Fri Feb 26 09:07:02 CST 2021, time=2021-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268325, encodeId=8d42126832585, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Sep 17 03:07:02 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498771, encodeId=a13a1498e71c5, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Sep 17 03:07:02 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885610, encodeId=114b88561058, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/27/9fdee81ba9771b6af046150adc14ee91.jpg, createdBy=54572576350, createdName=绝望的人没有故乡, createdTime=Wed Sep 16 07:47:34 CST 2020, time=2020-09-16, status=1, ipAttribution=)]

相关资讯

J Hepatology:HCV的治疗可降低与病毒性肝炎相关的死亡率

直接作用抗病毒药(DAA)彻底改变了慢性HCV感染患者的治疗方式。

ESC 2020:2型糖尿病患者心肌梗死发病率和死亡率趋势

线上举行的欧洲心脏病学会年会(ESC 2020)LBS专场,重磅推出丹麦研究团队的一项颇具思考性的重要研究,该研究探索了丹麦全国范围内2型糖尿病患者的心梗和死亡风险趋势,研究结果非常引人注目。

JAHA:银屑病对心肌梗死患者死亡率和结局的影响

在所有MI病例中,只有0.3%的患者被诊断为银屑病,而患有银屑病的MI患者比没有银屑病的MI患者中位年龄要小5岁。银屑病似乎可以增加已知心血管危险因素的患病率。

Cancer:接受根治性前列腺切除术后的前列腺癌死亡率的种族差异

尽管前列腺癌生存率的种族差异已被详细的记录,但导致差异的各种因素的相对重要性人们仍不清楚。也少有研究考察白人与西班牙裔、白人与亚裔美国人和太平洋岛民(AAPIs)之间的差异。

Heart:缺血性心衰患者射血分数改善与死亡率

缺血性心肌病患者在24个月时LVEF改善≥10%并不常见,接受CABG和药物治疗的患者与单独接受药物治疗的患者之间无差异,并与患者死亡风险降低独立相关。

Aliment Pharmacol Ther :多喝咖啡,就可以降低近一半的肝病死亡率?

肝病是导致人类健康的杀手之一,据统计,全球每年约超过100万人死于肝硬化,约七十四万人因肝硬化引发的肝癌死亡,占每年总死亡人数的3.5%以上。